Previous Close | 102.85 |
Open | 103.65 |
Bid | 103.35 x 20000 |
Ask | 104.15 x 20000 |
Day's Range | 103.65 - 103.65 |
52 Week Range | 68.80 - 106.30 |
Volume | |
Avg. Volume | 32 |
Market Cap | 25.211B |
Beta (5Y Monthly) | 0.69 |
PE Ratio (TTM) | 44.48 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.85 (1.79%) |
Ex-Dividend Date | Mar 28, 2024 |
1y Target Est | N/A |
Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2024 on May 2, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.
Cardinal Health (NYSE: CAH) today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions reduction targets. Targets are considered science-based if they align with what the latest climate science says is necessary to limit global warming to 1.5°C above pre-industrial levels.
Today, Cardinal Health (NYSE: CAH) released its 2024 Biosimilars Report: insights on a pivotal year of evolution and expansion, an analysis of key recent economic, competitive, legislative and societal developments in biosimilars. The publication highlights legislative developments and new treatments, including adalimumab biosimilars. The report also provides the perspectives of retina specialists on biosimilars, ahead of the expected launch of multiple new biosimilars for retinal diseases.